GlassScriptPhysician profile
Peishan Wu
NPI 1487304911
$1,396.63
in general payments reported to CMS, 2019-2025
10 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $660 · 2024: $19.29 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946 · Travel and Lodging: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.19 |
| Travel and Lodging | $186.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $583.15 | 2022-2023 | Visumax |
| Alcon Vision LLC | $325.05 | 2025 | Tryptyr, Dailies Total1 |
| Coopervision INC. | $118.57 | 2022 | |
| Oyster Point Pharma, INC. | $101.80 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $88.28 | 2023-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $81.66 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $31.47 | 2025 | |
| Rxsight INC | $24.99 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $21.66 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $20.00 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peishan Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.